Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Manuscript
  • Published:

Immunotherapy

Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines

Abstract

Calicheamicin-conjugated humanized anti-CD33 mouse monoclonal antibody, CMA-676, has recently been introduced to clinics as a promising drug to treat patients with acute myeloid leukemia (AML) in relapse. However, the mechanism of action of CMA-676 has not been well elucidated. The cytotoxic effect of CMA-676 on HL60, NOMO-1, NB4, NKM-1, K562, Daudi, and the multidrug-resistant sublines, NOMO-1/ADR and NB4/MDR, was investigated by cell cycle distribution and morphology. These studies were done by a video-microscopic system, DNA fragmentation, dye exclusion and 3H-thymidine uptake after analysis of CD33, CD34, P-glycoprotein (P-gp), multidrug resistance (MDR)-associated protein and lung-related protein on these cells. A dose-dependent, selective cytotoxic effect of CMA-676 was observed in cell lines that expressed CD33, and was dependent on the amount of CD33 and the proliferative speed of the cells. Sensitive cells were temporally arrested at the G2/M phase before undergoing morphological changes. CMA-676 is not effective on P-gp-expressing multidrug-resistant sublines compared with parental cell lines. MDR modifiers, MS209 and PSC833, restored the cytotoxic effect of CMA-676 in P-gp-expressing sublines. CMA-676 is a promising agent in the treatment of patients with AML that expresses CD33. The combined use of CMA-676 and MDR modifiers may increase the selective cytotoxic effect in multidrug-resistant AML.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Prices vary by article type

from$1.95

to$39.95

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9

Similar content being viewed by others

References

  1. Marie J . P-glycoprotein in Adult Hematologic Malignancies Saunders: Philadelphia, PA 1995

    Google Scholar 

  2. List AF . The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia Leukemia 1996 10: S36–S38

    Google Scholar 

  3. Willman CL . The prognostic significance of the expression and function of multidrug-resistance transporter proteins in acute myeloid leukemia: studies of Southwest Oncology Group Leukemia Research Program Semin Hematol 1997 34: 25–33

    CAS  Google Scholar 

  4. Miyawaki S, Tanimoto M, Kobayashi T, Minami S, Tamura J, Hatake K, Kuriyama K, Ohmoto E, Saito K, Kanamaru A, Oho H, Ohtake S, Jinnai I, Sakamaki H, Yamada O, Asou N, Takahashi M, Takeyama K, Matsuda S, Ueda R, Ohno R . Randomized study of individualized induction therapy with or without etoposide in adult acute myeloid leukemia (except for M3) (JALSG-AML92 study) and analysis of prognostic factors Blood 1997 90: (Suppl. 1) 503a (Abstr.)

    Google Scholar 

  5. Takeshita A, Shinjo K, Naito K, Fujisawa S, Shigeno K, Ohnishi K, Naoe T, Ohno R . No role of P-glycoprotein (P-gp) to all-trans retinoic acid (ATRA) resistance in acute promyelocytic leukemia (APL) cells: analysis of P-gp and intra-cellular concentration of ATRA Blood 1998 92: (Suppl. 1) 597a (Abstr.)

    Google Scholar 

  6. Tobita T, Takeshita A, Kitamura K, Ohnishi K, Yanagi M, Hiraoka A, Karasuno T, Takeuchi M, Miyawaki S, Ueda R, Naoe T, Ohno R . Treatment with a new synthetic retinoid, Am80, of acute promyelocytic leukemia relapsed from complete remission induced by all-trans retinoic acid Blood 1997 90: 967–973

    CAS  Google Scholar 

  7. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY . Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients Blood 1997 89: 3354–3360

    CAS  Google Scholar 

  8. Multani PS, Grossbard ML . Monoclonal antibody-based therapies for hematologic malignancies J Clin Oncol 1998 16: 3691–3710

    CAS  Google Scholar 

  9. Buchsbaum DJ, Lawrence TS . Tumor therapy with radiolabeled monoclonal antibodies Antibody Immunocon Radiopharm 1991 4: 245–272

    Google Scholar 

  10. Fritzberg AR, Baumier PL, Bottino BJ, Reno JM . Approaches to improved antibody- and peptide-mediated targeting for imaging and thrapy of cancer J Control Release 1994 28: 167–173

    CAS  Google Scholar 

  11. Bagshawe KD . Antibody-directed enzyme prodrug therapy (ADEPT) J Control Release 1994 28: 187–193

    CAS  Google Scholar 

  12. Brinkmann U, Pastan I . Immunotoxins against cancer Biochim Biophys Acta 1994 1198: 27–45

    CAS  Google Scholar 

  13. Freeman SD, Kelm S, Barber EK, Crocker PR . Characterization of CD33 as a new member of the sialoadesin family of cellular interaction molecules Blood 1995 85: 2005–2012

    CAS  Google Scholar 

  14. Wagner JE, Collins D, Fuller S, Schain LR, Berson AE, Almici C, Hall MA, Chen KE, Okarma TB, Lebkowski JS . Isolation of small, primitive human hematopoietic stem cells: distribution of cell surface cytokine receptors and growth in SCID-Hu mice Blood 1995 86: 512–523

    CAS  Google Scholar 

  15. Sievers EL, Appelbaum FR, Spielberger RT, Forman SJ, Flowers D, Smith FO, Shannon-Dorcy K, Berger MS, Bernstein ID . Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate Blood 1999 93: 3678–3684

    CAS  Google Scholar 

  16. Schwartz MA, Lovett DR, Redner A, Finn RD, Graham MC, Divgi CR, Dantis L, Gee TS, Andreeff M, Old LJ . Dose-escalation trial of M195 labeled with iodine 131 for cytoreduction and marrow ablation in relapsed or refractory myeloid leukemias J Clin Oncol 1993 11: 294–303

    CAS  Google Scholar 

  17. Jurcic JG, Philip CC, Nikura TK, Paradopoulos EB, Finn RD, Gansow OA, Miller WHJr, Geerlings MW, Warrell RPJr, Larson SM, Scheinberg DA . Radiolabeled anti-CD33 monoclonal antibody M195 for myeloid leukemias Cancer Res 1995 55: 5908s–5910s

    CAS  Google Scholar 

  18. Juric JG, Deblasio A, Dumont L, Warrell RPJr, Scheinberg DA . Molecular remission induction without relapse after anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia (APL) Blood 1997 90: (Suppl. 1) 416a (Abstr.)

    Google Scholar 

  19. Juric JG, McDevitt MR, Sgooros G, Ballangrud A, Finn RD, Geerlings MW, Humm JL, Molinet R, Apostolidis C, Larson SM, Scheinberg DA . Targeted alpha-particle thrapy for myeloid leukemias: a phase I trial of bismuth-213-HuM195 (anti-CD33) Blood 1997 90: (Suppl. 1) 504a (Abstr.)

    Google Scholar 

  20. Pagliaro LC, Liu B, Munker R, Andreeff M, Freireich EJ, Scheinberg DA, Rosenblum MG . Humanized M195 monoclonal antibody conjugated to recombinant gelonin: an anti-CD33 immunotoxin with antileukemic activity Clin Cancer Res 1998 4: 1971–1976

    CAS  Google Scholar 

  21. Roy DC, Griffin JD, Belvin M, Blattler WA, Lambert JM, Ritz J . Anti-MY9-blocked-ricin: an immunotoxin for selective targeting of acute myeloid leukemia cells Blood 1991 77: 2404–2412

    CAS  Google Scholar 

  22. Lee MD, Dunne TS, Siegel MM, Chang CC, Morton GO, Borders DB . Calicheamicins, a novel family of antitumor antibiotics. 1: Chemistry and partial structure of calicheamicin γ1I J Am Chem Soc 1987 109: 3464–3466

    CAS  Google Scholar 

  23. Lee MD, Dunne TS, Chang CC, Ellestad GA, Siegel MM, Morton GO, McGahren WJ, Borders DB . Calicheamicins, a novel family of antitumor antibiotics. 2: Chemistry and structure of calicheamicin γ1I J Am Chem Soc 1987 109: 3466–3468

    CAS  Google Scholar 

  24. Zein N, Poncin M, Nilakantan R, Ellestad GA . Calicheamicin γ1I and DNA: molecular recognition process responsible for site-specificity Science 1989 244: 697–699

    CAS  Google Scholar 

  25. Hangeland JJ, De Voss JJ, Heath JA, Townsend CA . Specific abstraction of the 5′ (S)- and 4′-deoxyribosyl hydrogen atoms from DNA by calicheamicin γ1I J Am Chem Soc 1992 114: 9200–9202

    CAS  Google Scholar 

  26. Sievers EL, Larson RA, Estey E, Stadtmauer E, Berger M, Eten C, Bernstein I, Applebaum F . Interim analysis of the efficacy and safety of CMA-676 in patients with AML in first relapse Blood 1998 92: (Suppl. 1) 613a (Abstr.)

    Google Scholar 

  27. Nicolaou KC, Li T, Nakada M, Hummel CW, Hiatt A, Wrasidlo W . Calicheamicin θI1: a rationally designed molecule with extremely potent and selective DNA cleaving properties and apoptosis inducing activity Angew Chem Int Ed Engl 1994 33: 183–186

    Google Scholar 

  28. Zhao B, Konno S, Wu JM, Oronsky AL . Modulation of nicotinamide adenine dinucleotide and poly (adenocine diphosphoribose) metabolism by calicheamicin γ1 in human HL-60 cells Cancer Lett 1990 50: 141–147

    CAS  Google Scholar 

  29. Tsuruo T, Saito H, Kawabata H, Ohhara T, Hamada H, Utakoji T . Characteristics of resistance to Adriamycin in human myelogenous leukemia K562 resistant to Adriamycin and in isolated clones Jpn J Cancer Res 1986 77: 682–692

    CAS  Google Scholar 

  30. Hamaguchi M, Morishita Y, Takahashi I, Ogura M, Takamatsu J, Saito H . FDP D-dimer induces the serection of interleukin-1, urokinase-type plasminogen activator, and plasminogen activator inhibitor-2 in human promyelocytic leukemia cell line Blood 1991 77: 94–100

    CAS  Google Scholar 

  31. Takeshita A, Shinjo K, Ohnishi K, Ohno R . New flow cytometric method for detection of minimally expressed multidrug resistance P-glycoprotein on normal and acute leukemia cells using biotinylated MRK16 and streptavidin-RED670 conjugate Jpn J Cancer Res 1995 86: 607–615

    CAS  Google Scholar 

  32. Takeshita A, Shinjo K, Ohnishi K, Ohno R . Expression of multidrug resistance P-glycoprotein in myeloid progenitor cells of different phenotype: comparison between normal bone marrow cells and leukemia cells Br J Haematol 1996 93: 18–21

    CAS  Google Scholar 

  33. Den Boer ML, Zwaan CM, Pieters R, Kazemier KM, Rottier MM, Flens MJ, Scheper RJ, Veerman AJ . Optimal immunocytochemical and flow cytometric detection of P-gp, MRP and LRP in childhood acute lymphoblastic leukemia Leukemia 1997 11: 1078–1085

    CAS  Google Scholar 

  34. Overton WR . Modified histogram subtraction technique for analysis of flow cytometry data Cytometry 1998 9: 619–626

    Google Scholar 

  35. Muller MR, Lennartz K, Nowrousian MR, Dux R, Tsuruo T, Rajewsky MF, Seeber S . Improved flow-cytometric detection of lowP-glycoprotein expression in leukaemic blasts by histogram subtraction analysis Cytometry 1994 15: 64–72

    CAS  Google Scholar 

  36. Terakawa S, Fan JH, Kumakura K, Ohara-Imaizumi M . Quantitative analysis of exocytosis directly visualized in living chromaffin cells Neurosci Lett 1991 11: 82–86

    Google Scholar 

  37. Sellins KS, Cohen JJ . Gene induction by gamma-irradiation leads to DNA fragmentation in lymphocytes J Immunol 1987 139: 3199–3206

    CAS  Google Scholar 

  38. Kartner N, Evernden-Porelle D, Bradley G, Ling V . Detection of P-glycoprotein in multidrug-resistant cell lines by monoclonal antibodies Nature 1985 316: 820–823

    CAS  Google Scholar 

  39. Gottesman MM, Pastan I, Ambudkar SV . P-glycoprotein and multidrug resistance Curr Opin Genet Dev 1996 6: 610–617

    CAS  Google Scholar 

  40. Baba M, Nakanishi O, Sato W, Saito A, Miyama Y, Yano O, Shimada S, Fukazawa N, Naito M, Tsuruo T . Relationship between multidrug resistant gene expression and multidrug resistant-reversing effect of MS-209 in various tumor cells Cancer Chemother Pharmacol 1995 36: 361–367

    CAS  Google Scholar 

  41. Friche E, Jensen PB, Nissen NI . Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor Cancer Chemother Pharmacol 1992 30: 235–237

    CAS  Google Scholar 

Download references

Acknowledgements

We would like to express our sincere gratitude to Ms Yoshimi Suzuki, Ms Noriko Anma, Ms Naoko Sugiura, and Ms Keiko Natsume for technical assistance and to Dr Kiyoshi Shibata (Equipment Centre, Hamamatsu University School of Medicine) for his co-operation. We are indebted to Wyeth-Ayerst Research Division of American Home Products for supply of test substances.

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Naito, K., Takeshita, A., Shigeno, K. et al. Calicheamicin-conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab zogamicin, CMA-676) shows cytocidal effect on CD33-positive leukemia cell lines, but is inactive on P-glycoprotein-expressing sublines. Leukemia 14, 1436–1443 (2000). https://doi.org/10.1038/sj.leu.2401851

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.leu.2401851

Keywords

This article is cited by

Search

Quick links